Amin Khan PhD GreenLight Biosciences, Inc.

Dr. Amin Khan joined GreenLight Biosciences in April, 2021 as Chief Science Officer, Human Health. Prior to joining this mRNA-based biotech company, he spent 25+ years in pharmaceutical and vaccines R&D, encompassing small and large molecule drugs, biologics and vaccines. Most recently, he has led technical R&D teams at Novartis and GSK, where his teams's contributions enabled the development and launch of Bexsero® and Shingrix®, vaccines, and the accelerated development of mid-stage vaccine assets, including for RSV, HSV, and CMV. He also held accountability for scientific gating and prioritization of GSK’s vaccine discovery portfolio. Dr. Khan led GSK Vaccines R&D Acceleration (March 2019 – March 2021) with accountability for end-to-end acceleration of the vaccine portfolio. He joined GSK (2015) to head Global Vaccines Technical R&D, having held an equivalent position at Novartis Vaccines (2011-2015). Prior to joining the vaccines industry, Dr. Khan spent more than 20 years working on small molecule drug, and biotherapeutic product, process and analytical development; Trinity Biosystems, Inc (2008-2010), Eli Lilly and Company (1998-2008), West Pharmaceutical Services (1993-1998), and Enzytech, Inc (1989-1993). He holds a Ph.D., in Pharmaceutical Sciences from the University of Nottingham, U.K.